CTLA4 and melanoma: Envisioning this as an important anti-cancer tool, the first immune checkpoint inhibitor (ipilimumab) was developed against CTLA-4 in 1996 and subsequently approved by the FDA in 2011 for treatment in advanced melanoma [20,21].